CAMP - CAMP4 THERAPEUTICS CORPORATION logo

CAMP

CAMP4 THERAPEUTICS CORPORATION

Net -55.25%top 1%Rev 436.50%top 1%Revenue grew 100% of years1Y
Hold

Camp4 Therapeutics Corporation develops RNA-based therapeutics targeting genetic diseases, focusing on central nervous system and liver disorders. Its lead candidates include CMP-001 for urea cycle disorders and CMP-002 for SYNGAP1-related conditions.

โš•๏ธ Healthcare NASDAQ Listed 2024 $ USD
$1,000 invested 1 year ago โ†’$3,283today

Score Overview

1 Year
Scoreโ€”
Net Growth-55.25%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth436.50%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-55.25%
Net TrendNever
Net Income Consistencyโ€”
Rev Growth436.50%
Rev TrendEvery year
Revenue Consistencyโ€”

See the full market ranking โ†’

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.53โ€”
1 Year2025-08-12
$ 1.38228.26%
All Time2024-10-11
$ 10.72-57.74%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 3M-$ 80M$ 109M
IPO2024$ 652K-$ 51M$ 64M

Explore beyond CAMP

You're looking at CAMP4 THERAPEUTICS CORPORATION. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies